Clinical TrialApr 13, 2026, 08:31 AM
RVMD: Daraxonrasib Phase 3 Shows 13.2-Month OS in Pancreatic Cancer
AI Summary
Revolution Medicines, Inc. announced positive topline results from its Phase 3 RASolute 302 clinical trial for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The oral drug demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy. Daraxonrasib achieved a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40. The company plans to submit these data to global regulatory authorities, including the U.S. FDA.
Key Highlights
- Daraxonrasib showed median OS of 13.2 months vs 6.7 months for chemotherapy.
- Hazard ratio for overall survival was 0.40 (p < 0.0001).
- Demonstrated statistically significant and clinically meaningful improvements in PFS and OS.
- Daraxonrasib was generally well tolerated with a manageable safety profile.
- Company plans to submit data to global regulatory authorities, including the US FDA.